Just checked ANI's Q4 earnings and the company actually beat Wall Street expectations pretty solidly. They pulled in $247M in revenue, up nearly 30% year-over-year, which came in about 6% ahead of what analysts were expecting at $233M. The earnings per share of $2.33 was even more impressive - that's a 17% beat versus the $1.99 consensus estimate.

What caught my eye looking at the breakdown: ANI's generic pharma segment absolutely crushed it with $100.76M in revenue, blowing past analyst estimates of $86.36M. That's a 28% jump from the same quarter last year. The rare disease and specialty brands segment also showed strength with $143.59M, though that came in slightly below the $144M estimate. Their Cortrophin Gel product brought in $111.43M, which was a bit light versus the $114M expected.

The generics and other revenue hit $103.47M compared to the $91.74M estimate, so that's another area where ANI outperformed. Royalties and other services came in at $2.71M versus an expected $3.2M - the only real miss in the report.

Stock-wise, ANI shares are down about 6% over the past month while the broader market is basically flat, so there's been some weakness despite the solid earnings beat. Zacks has it rated as a Buy though. Overall, this was a pretty strong quarter for ANI with solid execution across most segments.